News Details

IMAC Holdings Receives FDA Authorization to Initiate Clinical Study of Its Umbilical Cord-Derived Allogenic Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson’s Disease

About IMAC Holdings, Inc.
  • NASDAQ: $IMAC
  • Notified: $1.84
  • 11:58 EDT

Price Chart